Payload Information

General Information of This Payload
Payload ID
PAY0VEOTQ
Name
clezutoclax
Synonyms
Clezutoclax
   Click to Show/Hide
Target Bcl-2-like protein 1 (BCL2L1)
 Target Info 
Structure
Formula
C46H55N7O6S
Isosmiles
CC1=C(C=NN1CC23CC4(CC(CC(C2)(C4)C)(C3)C)OCCNCC[C@H](CO)O)C5=CC=C(N=C5C(O)=O)N6CCC7=CC=CC(C(NC8=NC9=CC=CC=C9S8)=O)=C7C6
PubChem CID
124082768
InChI
InChI=1S/C46H55N7O6S/c1-29-34(19-48-53(29)28-45-23-43(2)22-44(3,24-45)26-46(25-43,27-45)59-18-16-47-15-13-31(55)21-54)32-11-12-38(50-39(32)41(57)58)52-17-14-30-7-6-8-33(35(30)20-52)40(56)51-42-49-36-9-4-5-10-37(36)60-42/h4-12,19,31,47,54-55H,13-18,20-28H2,1-3H3,(H,57,58)(H,49,51,56)/t31-,43?,44?,45?,46?/m1/s1
InChIKey
JDRWPKNPESVAQP-OBRWPCRASA-N
Pharmaceutical Properties
Molecule Weight
834.056
Polar area
174.96
Complexity
2330.002045
xlogp Value
6.84512
Heavy Count
60
Rot Bonds
15
Hbond acc
12
Hbond Donor
5
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
Mirzotamab clezutoclax [Phase 1]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Patients Enrolled
Inclusion: Solid tumor patients (Part 2a: SCLC; Part 2b: NSCLC/HR+HER2- breast cancer) with measurable disease, ECOG ≤2, prior therapy failure. Breast cancer patients must have CDK4/6 inhibitor failure; NSCLC patients require targeted therapy if actionable mutations present. Exclusion: Active CNS metastases, Grade≥2 neuropathy, unresolved toxicities, active hepatitis/HIV, significant cardiac history, or hypersensitivity to study drug components. Taxane-exposed patients require 2-month washout.

   Click to Show/Hide
Administration Dosage
Participants will be administered ABBV-155 (various doses).
Related Clinical Trial
NCT Number NCT03595059  Phase Status PHASE1
Clinical Description
A Phase 1 First-in-Human Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
Primary Endpoint
Primary endpoints include MTD/RPTD determination during dose escalation (21-day evaluation) and ORR assessment (RECIST 1.1) with 2-6 month follow-up in expansion phases.
Other Endpoint
Secondary objectives comprise AE monitoring (12 months), efficacy measures (DOR/CR/PFS/OS), PK parameters (Cmax/Tmax/AUCt/AUCinf/t1/2 over 48 days), and cardiac safety (QTcF changes).
References
Ref 1 A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors